These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18544941)

  • 1. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy.
    Tanaka E; Matsumoto A; Yoshizawa K; Maki N
    Intervirology; 2008; 51 Suppl 1():3-6. PubMed ID: 18544941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients.
    Suzuki F; Miyakoshi H; Kobayashi M; Kumada H
    J Med Virol; 2009 Jan; 81(1):27-33. PubMed ID: 19031469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance.
    Tanaka E; Matsumoto A; Suzuki F; Kobayashi M; Mizokami M; Tanaka Y; Okanoue T; Minami M; Chayama K; Imamura M; Yatsuhashi H; Nagaoka S; Yotsuyanagi H; Kawata S; Kimura T; Maki N; Iino S; Kiyosawa K;
    Liver Int; 2006 Feb; 26(1):90-6. PubMed ID: 16420514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fundamental and clinical evaluation of hepatitis B virus core-related antigen assay by LUMIPULSE f].
    Tanaka Y; Takagi K; Hiramatsu K; Naganuma H; Iida T; Takasaka Y; Mizokami M
    Rinsho Byori; 2006 Jul; 54(7):692-8. PubMed ID: 16913659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment.
    Rokuhara A; Tanaka E; Matsumoto A; Kimura T; Yamaura T; Orii K; Sun X; Yagi S; Maki N; Kiyosawa K
    J Viral Hepat; 2003 Jul; 10(4):324-30. PubMed ID: 12823601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of serum hepatitis B virus large surface protein determination in lamivudine anti-viral therapy for patients with hepatitis B].
    Li GY; Sheng JL; Huang HJ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):133-5. PubMed ID: 18574538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.
    Matsuzaki T; Tatsuki I; Otani M; Akiyama M; Ozawa E; Miuma S; Miyaaki H; Taura N; Hayashi T; Okudaira S; Takatsuki M; Isomoto H; Takeshima F; Eguchi S; Nakao K
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1217-22. PubMed ID: 23432697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary study on the efficacy and safety of lamivudine and interferon alpha therapy in decreasing serum HBV DNA level in HBV positive transgenic mice during pregnancy.
    Li D; Xu DZ; Choi BC; Men K; Zhang JX; Lei XY; Yan YP
    J Med Virol; 2005 Jun; 76(2):203-7. PubMed ID: 15834875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
    Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction and application of a genechip method for detection of hepatitis B virus lamivudine-resistant mutants and basal core promotor/Pre-C mutants].
    Li B; Zhou BP; Peng JF; Chen LY; Zhang W; Tang W; Wang ZQ; Yin ZH; Xu LM; Luo RL; Li XH; Liu SY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Aug; 23(4):309-12. PubMed ID: 20108783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma.
    Kim JH; Park JW; Koh DW; Lee WJ; Kim CM
    Liver Int; 2009 Feb; 29(2):203-7. PubMed ID: 18662281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory: two quantitative hepatitis B surface antigen assays and an HBV core-related antigen assay.
    Park Y; Hong DJ; Shin S; Cho Y; Kim HS
    Am J Clin Pathol; 2012 May; 137(5):770-7. PubMed ID: 22523216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical application of microarray technique to quantify the lamivudine-resistant gene mutant of hepatitis B virus].
    Huang XT; Zeng AP; Lin F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):185-7. PubMed ID: 17653332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
    Knöll A; Boehm S; Hahn J; Holler E; Jilg W
    J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
    Selabe SG; Song E; Burnett RJ; Mphahlele MJ
    J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial of lamivudine in hepatitis B surface antigen carriers with persistent hepatitis B core IgM antibody.
    Ali HY
    Saudi Med J; 2003 Sep; 24(9):996-9. PubMed ID: 12973486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B.
    Cheong JY; Cho SW; Yoo JH; Hong SP; Kim SO; Yoo WD; Kim JH
    Hepatogastroenterology; 2008; 55(84):1029-33. PubMed ID: 18705323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers.
    Kim JK; Lee HJ; Lee YJ; Chun JY; Lee IK; Lim YS; Suh DJ; Ko SY; Kim MH; Oh HB
    J Virol Methods; 2008 Apr; 149(1):76-84. PubMed ID: 18291537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.
    Kumar M; Sarin SK
    Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):465-95. PubMed ID: 19072396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.